
Steven E Arnold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6935057/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 2012, 122, 1316-1338.	3.9	1,431
2	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews Neurology, 2018, 14, 168-181.	4.9	905
3	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	3.7	448
4	Effects of the Insulin Sensitizer Metformin in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2017, 31, 107-113.	0.6	243
5	Higher C-Reactive Protein Levels Predict Postoperative Delirium in Older Patients Undergoing Major Elective Surgery: A Longitudinal Nested Case-Control Study. Biological Psychiatry, 2017, 81, 145-153.	0.7	100
6	High Câ€Reactive Protein Predicts Delirium Incidence, Duration, and Feature Severity After Major Noncardiac Surgery. Journal of the American Geriatrics Society, 2017, 65, e109-e116.	1.3	93
7	Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. Annals of Neurology, 2020, 88, 513-525.	2.8	57
8	Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. Proteomes, 2018, 6, 32.	1.7	52
9	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 575953.	1.1	45
10	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	3.3	41
11	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimer's and Dementia, 2022, 18, 645-653.	0.4	39
12	Association of Cancer History with Alzheimer's Disease Dementia and Neuropathology. Journal of Alzheimer's Disease, 2017, 56, 699-706.	1.2	35
13	Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination. , 2017, 13, 947-952.		35
14	VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Communications, 2021, 3, fcab261.	1.5	35
15	Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurology, 2022, 79, 478.	4.5	35
16	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Medicine, 2020, 18, 140.	2.3	34
17	Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. Neurobiology of Aging, 2021, 105, 99-114.	1.5	32
18	The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. PLoS ONE, 2018, 13, e0193707.	1.1	30

STEVEN E ARNOLD

#	Article	IF	CITATIONS
19	Fuzzy Entropy Metrics for the Analysis of Biomedical Signals: Assessment and Comparison. IEEE Access, 2019, 7, 104833-104847.	2.6	29
20	The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. Journal of Medicinal Chemistry, 2021, 64, 17656-17689.	2.9	28
21	Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients. Journal of the Neurological Sciences, 2021, 430, 120023.	0.3	27
22	Apolipoprotein E genotype and the association between Câ€reactive protein and postoperative delirium: Importance of geneâ€protein interactions. Alzheimer's and Dementia, 2020, 16, 572-580.	0.4	21
23	Clinical Trials and Tribulations in the COVID-19 Era. American Journal of Geriatric Psychiatry, 2020, 28, 913-920.	0.6	19
24	Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 58.	3.0	18
25	The Role of Inflammation after Surgery for Elders (RISE) study: Examination of [11C]PBR28 binding and exploration of its link to post-operative delirium. NeuroImage: Clinical, 2020, 27, 102346.	1.4	17
26	Plasma and cerebrospinal fluid inflammation and the blood-brain barrier in older surgical patients: the Role of Inflammation after Surgery for Elders (RISE) study. Journal of Neuroinflammation, 2021, 18, 103.	3.1	17
27	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis postâ€mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035.	2.1	15
28	Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease. Frontiers in Neurology, 0, 13, .	1.1	15
29	I <i>GF2R</i> circular RNA hsa_circ_0131235 expression in the middle temporal cortex is associated with AD pathology. Brain and Behavior, 2021, 11, e02048.	1.0	12
30	Consensus Approaches to Identify Incident Dementia in Cohort Studies: Systematic Review and Approach in the Successful Aging after Elective Surgery Study. Journal of the American Medical Directors Association, 2017, 18, 1010-1018.e1.	1.2	11
31	Multicrossover Randomized Controlled Trial Designs in <scp>A</scp> lzheimer Disease. Annals of Neurology, 2018, 84, 168-175.	2.8	11
32	The Role of Inflammation after Surgery for Elders (RISE) study: Study design, procedures, and cohort profile. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 752-762.	1.2	11
33	Brain insulin signaling and cerebrovascular disease in human postmortem brain. Acta Neuropathologica Communications, 2021, 9, 71.	2.4	11
34	Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. JCI Insight, 2022, 7, .	2.3	11
35	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Communications, 2022, 4, .	1.5	11
36	Task-related fMRI BOLD response to hyperinsulinemia in healthy older adults. JCI Insight, 2019, 4, .	2.3	8

#	Article	IF	CITATIONS
37	Brain IGFBP-5 modifies the relation of depressive symptoms to decline in cognition in older persons. Journal of Affective Disorders, 2019, 250, 313-318.	2.0	7

Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias. Focus (American) Tj ETQq0 0 0 grgBT /Overlock 10 T

39	Patterns and Persistence of Perioperative Plasma and Cerebrospinal Fluid Neuroinflammatory Protein Biomarkers After Elective Orthopedic Surgery Using SOMAscan. Anesthesia and Analgesia, 2023, 136, 163-175.	1.1	6
40	Insulin and adipokine signaling and their cross-regulation in postmortem human brain. Neurobiology of Aging, 2019, 84, 119-130.	1.5	5
41	A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimer's Disease. Metabolites, 2022, 12, 181.	1.3	5
42	Detection of Oculomotor Dysmetria From Mobile Phone Video of the Horizontal Saccades Task Using Signal Processing and Machine Learning Approaches. IEEE Access, 2022, 10, 34022-34031.	2.6	4
43	Proteomic characterization of post-mortem human brain tissue following ultracentrifugation-based subcellular fractionation. Brain Communications, 2022, 4, .	1.5	3
44	Plasma biomarkers of neuroinflammation and vascular injury predict cognitive decline in patients with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e046134.	0.4	2
45	"Senior Moments―or More? Diagnostic Evaluation of Cognitive Complaints in Older Adults and the Role of Cerebrospinal Fluid Biomarkers. journal of applied laboratory medicine, The, 2020, 5, 219-224.	0.6	1
46	Active deep learning to detect cognitive concerns in electronic health records. Alzheimer's and Dementia, 2021, 17, e055362.	0.4	1
47	Levels of the synaptic proteins PSDâ€95, SNAPâ€25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
48	P2â€107: Brain Insulin Resistance and Alzheimer's Disease Neuropathology Among Older Autopsied Persons With and Without Diabetes. Alzheimer's and Dementia, 2016, 12, P653.	0.4	0
49	P2â€⊋79: CSF SMALL RNA BIOMARKERS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P785.	0.4	0
50	P1â€⊋74: A TARGETED MASSâ€SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P387.	0.4	0
51	P3â€⊋20: ULTRAâ€SENSITIVE DETECTION OF CENTRAL NERVOUS SYSTEM BIOMARKERS IN BLOOD. Alzheimer's and Dementia, 2018, 14, P1155.	0.4	0
52	P3â€037: CLINICAL TRIAL DESIGN FOR A PHASE II, RANDOMIZED, PLACEBOâ€CONTROLLED TRIAL OF AMX0035 II ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1078.	N 0.4	0
53	A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. Trials, 2020, 21, 1016.	0.7	0
54	Apolipoprotein E genotype and the relationship between chitinase 3â€like protein 1 and postoperative delirium: Potential geneâ€protein interactions. Alzheimer's and Dementia, 2020, 16, e040595.	0.4	0

STEVEN E ARNOLD

#	Article	IF	CITATIONS
55	Brain transcriptomes and plasma proteins reveal upregulation of a proinflammatory signature in APOE e4 carriers. Alzheimer's and Dementia, 2020, 16, e041316.	0.4	ο
56	Development of a robust and stable mass based spectrometry method for analysis of Alzheimer's disease biomarkers in human cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e042035.	0.4	0
57	A pilot multiple crossover, randomized controlled trial of methylphenidate in mild cognitive impairment using standardized tests and daily brain games to track cognition. Alzheimer's and Dementia, 2020, 16, e043188.	0.4	0
58	Characterizing chromogranin and secretogranin proteoforms in dementia pathophysiology. Alzheimer's and Dementia, 2020, 16, e044624.	0.4	0
59	Plasma ILâ€12/IFNâ€Î³ axis predicts cognitive trajectories in cognitively normal older adults. Alzheimer's and Dementia, 2020, 16, e045497.	0.4	0
60	Technical performance and biotemporal stability evaluation of Olink proximity extension assay for bloodâ€based biomarker discovery. Alzheimer's and Dementia, 2021, 17, .	0.4	0
61	Altered brain functional connectivity and cardiovascular and metabolic risk factors in middleâ€aged and older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
62	Matrix metalloproteinaseâ€10 as a novel biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
63	The technical reliability and stability of ATN quantification using the Fujirebio Lumipulse G1200 fullyâ€automated immunoassay instrument in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
64	Characterizing proteoforms of the granin family of neuropeptides in dementia pathophysiology. Alzheimer's and Dementia, 2021, 17, e056265.	0.4	0
65	Using cerebrospinal fluid ATN quantification to classify research subjects in a diverse clinical population. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
66	A comparison of multiple platforms for quantifying ATN values in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, .	0.4	0
67	Brain insulin signaling in persons with and without diabetes is associated with cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
68	Characterization of novel neuropeptide proteolytic processing involved in dementia pathophysiology. Alzheimer's and Dementia, 2021, 17, e058553.	0.4	0
69	Brain insulin signaling and cerebrovascular disease in human postmortem brain Alzheimer's and Dementia, 2021, 17 Suppl 3, e052253.	0.4	Ο

5